1. NF-κB Autophagy Apoptosis
  2. NF-κB Autophagy Mitophagy Apoptosis IKK
  3. Parthenolide

Parthenolide  (Synonyms: パルテノリド; (-)-Parthenolide)

製品番号: HY-N0141 純度: 99.91%
COA 取扱説明書 Technical Support

Parthenolide is a sesquiterpene lactone found in the medicinal herb Feverfew. Parthenolide exhibits anti-inflammatory activity by inhibiting NF-κB activation; also inhibits HDAC1 protein without affecting other class I/II HDACs.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 20554-84-1

容量 価格(税別) 在庫状況 数量
>無料サンプル (0.1 - 0.2 mg)   今すぐ申し込む  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 66 在庫あり
Solution
10 mM * 1 mL in DMSO USD 66 在庫あり
Solid
50 mg $60 在庫あり
100 mg $84 在庫あり
200 mg $144 在庫あり
500 mg $260 在庫あり
1 g   お問い合わせ  
5 g   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 39 publication(s) in Google Scholar

Other Forms of Parthenolide:

Top Publications Citing Use of Products

顧客検証

Cell Imaging/Staining
In Vivo Efficacy Study
Histological Imaging/Staining
WB
Flow Cytometry
IF

    Parthenolide purchased from MedChemExpress. Usage Cited in: Cell Res. 2025 Apr 1.  [Abstract]

    Parthenolide (PTL; 10 μM; 1.5 h). Live cell images of HeLa cells stably expressing mNG-hNLRP3 untreated (Control), or pretreated with DMSO, or 10 μM PTL for 30 min, followed by 40 μg/mL Imiquimod for 1 h.

    Parthenolide purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2023 Jan-Dec;15(1):2221093.  [Abstract]

    Parthenolide (PTL; 10 mg/kg; ip). The weight of tumor in M, P, MT and MP groups on 90 day (n = 5) (M: EOC modeling; P: PTL i.P. after modeling; MT: oral gavage with fecal microbiota of patients with EOC after modeling; MP: oral gavage with fecal microbiota of patients with EOC meanwhile PTL i.P. after modeling).

    Parthenolide purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2023 Jan-Dec;15(1):2221093.  [Abstract]

    Parthenolide (PTL; 10 mg/kg; ip). H&E staining images of intestine tissues were presented after treatments of mice from M, P, MT and MP groups. (M: EOC modeling; P: PTL i.P. after modeling; MT: oral gavage with fecal microbiota of patients with EOC after modeling; MP: oral gavage with fecal microbiota of patients with EOC meanwhile PTL i.P. after modeling).

    Parthenolide purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2023 Jan-Dec;15(1):2221093.  [Abstract]

    Parthenolide (PTL; 10 mg/kg; ip). Western blot analysis in the expression of TLR − 4, MyD88, p-p65 and p65 in tumor tissues. (M: EOC modeling; P: PTL i.P. after modeling; MT: oral gavage with fecal microbiota of patients with EOC after modeling; MP: oral gavage with fecal microbiota of patients with EOC meanwhile PTL i.P. after modeling

    Parthenolide purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2020 Oct 6;6:97.  [Abstract]

    Representative flow cytometry histograms of iNOS+, or CD16+ BV2 cells under LPS stimulation for 24 h in the presence or absence of Parthenolide (PN; 1 μM).

    Parthenolide purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2020 Oct 6;6:97.  [Abstract]

    Representative images of F4/80 (red) and Arg1 (green) immunohistochemical staining of BV2 cells under LPS stimulation for 24 h in the presence or absence of Parthenolide (PN; 1 μM).

    NF-κB アイソフォーム固有の製品をすべて表示:

    IKK アイソフォーム固有の製品をすべて表示:

    • 生物活性

    • プロトコル

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Parthenolide is a sesquiterpene lactone found in the medicinal herb Feverfew. Parthenolide exhibits anti-inflammatory activity by inhibiting NF-κB activation; also inhibits HDAC1 protein without affecting other class I/II HDACs.

    IC50 & Target[1]

    NF-κB

     

    Autophagy

     

    Mitophagy

     

    IKKβ

     

    Cellular Effect
    Cell Line Type Value Description References
    A-431 IC50
    2.57 3
    Compound: Parthenolide
    Antiproliferative activity against human A431 wild type cells measured after 72 hrs by Sulforhodamine B assay
    Antiproliferative activity against human A431 wild type cells measured after 72 hrs by Sulforhodamine B assay
    [PMID: 31889606]
    A498 GI50
    7.04 3
    Compound: 1; PTL
    Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    A549 GI50
    91.8 3
    Compound: 1; PTL
    Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    A549 IC50
    22.03 3
    Compound: Parthenolide
    Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    [PMID: 27232656]
    A549 IC50
    >10 3
    Compound: Parthenolide
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 35090346]
    Bel-7402 IC50
    8.62 3
    Compound: PTL
    Antiproliferative activity against human Bel7402 incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Bel7402 incubated for 72 hrs by MTT assay
    [PMID: 31553932]
    Bel7402/5-FU IC50
    12.98 3
    Compound: PTL
    Antiproliferative activity against human Bel7402/5-FU incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Bel7402/5-FU incubated for 72 hrs by MTT assay
    [PMID: 31553932]
    Caco-2 IC50
    23.4 3
    Compound: Parthenolide
    Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    [PMID: 27232656]
    CAKI-1 GI50
    9.35 3
    Compound: 1; PTL
    Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    CCRF-CEM GI50
    9.16 3
    Compound: Parthenolide
    Growth inhibition of human CCRF-CEM cells
    Growth inhibition of human CCRF-CEM cells
    [PMID: 38107170]
    CCRF-CEM GI50
    9.16 3
    Compound: 1; PTL
    Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    COLO 205 GI50
    14.5 3
    Compound: 1; PTL
    Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    EKVX GI50
    17.3 3
    Compound: 1; PTL
    Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    EOL1 IC50
    7.5 3
    Compound: Parthenolide
    Cytotoxicity against human EOL-1 cells after 72 hrs by MTS assay
    Cytotoxicity against human EOL-1 cells after 72 hrs by MTS assay
    [PMID: 29350920]
    HCC 2998 GI50
    24.1 3
    Compound: 1; PTL
    Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    HCT-116 GI50
    10.8 3
    Compound: 1; PTL
    Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    HCT-15 GI50
    10.2 3
    Compound: 1; PTL
    Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    HEK293 IC50
    3.1 3
    Compound: Parthenolide
    Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    [PMID: 27232656]
    HeLa IC50
    2.1 3
    Compound: Parthenolide
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition incubated for 68 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition incubated for 68 hrs by MTT assay
    [PMID: 34665635]
    HeLa IC50
    23.08 3
    Compound: Parthenolide
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    [PMID: 27232656]
    HepG2 IC50
    5.6 3
    Compound: Parthenolide
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 68 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 68 hrs by MTT assay
    [PMID: 34665635]
    HL-60(TB) GI50
    5.71 3
    Compound: 1; PTL
    Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    HOP-62 GI50
    49 3
    Compound: 1; PTL
    Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    HOP-92 GI50
    13.5 3
    Compound: 1; PTL
    Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    HT-29 GI50
    23.5 3
    Compound: 1; PTL
    Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    IGROV-1 GI50
    21.1 3
    Compound: 1; PTL
    Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    K562 GI50
    22.6 3
    Compound: 1; PTL
    Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    KM12 GI50
    16.2 3
    Compound: 1; PTL
    Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    LOX IMVI GI50
    8.24 3
    Compound: 1; PTL
    Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    Malme-3M GI50
    13.8 3
    Compound: 1; PTL
    Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    MCF7 GI50
    16.4 3
    Compound: 1; PTL
    Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    MCF7 IC50
    >20 3
    Compound: Parthenolide
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay
    [PMID: 35665692]
    MCF7 IC50
    27.71 3
    Compound: Parthenolide
    Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    [PMID: 27232656]
    MCF7 IC50
    5.8 3
    Compound: PTD
    Growth inhibition of human MCF7 cells measured after 24 hrs by SRB assay
    Growth inhibition of human MCF7 cells measured after 24 hrs by SRB assay
    [PMID: 27448920]
    MDA-MB-231 IC50
    4.36 3
    Compound: Parthenolide
    Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    [PMID: 27232656]
    MEC1 EC50
    6.2 3
    Compound: 1; PTL
    Antiproliferative activity against human MEC1 cells assessed as reduction in cell viability by alamar blue assay
    Antiproliferative activity against human MEC1 cells assessed as reduction in cell viability by alamar blue assay
    [PMID: 32952998]
    MOLM-13 IC50
    10 3
    Compound: Parthenolide
    Cytotoxicity against human MOLM13 cells after 72 hrs by MTS assay
    Cytotoxicity against human MOLM13 cells after 72 hrs by MTS assay
    [PMID: 29350920]
    MOLT-4 GI50
    14.3 3
    Compound: 1; PTL
    Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    NCI/ADR-RES GI50
    15 3
    Compound: 1; PTL
    Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    NCI-H226 GI50
    20.5 3
    Compound: 1; PTL
    Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    NCI-H23 GI50
    20.2 3
    Compound: 1; PTL
    Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    NCI-H322M GI50
    21.7 3
    Compound: 1; PTL
    Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    NCI-H460 GI50
    18.8 3
    Compound: 1; PTL
    Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    NCI-H460 IC50
    9.6 3
    Compound: Parthenolide
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 35090346]
    NCI-H522 GI50
    5.47 3
    Compound: 1; PTL
    Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    OVCAR-3 GI50
    17.4 3
    Compound: 1; PTL
    Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    OVCAR-4 GI50
    21.5 3
    Compound: 1; PTL
    Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    OVCAR-5 GI50
    34.1 3
    Compound: 1; PTL
    Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    OVCAR-8 GI50
    17.1 3
    Compound: 1; PTL
    Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    PC-3 IC50
    >10 3
    Compound: Parthenolide
    Cytotoxicity against human PC-3 cells assessed as cell growth inhibition incubated for 68 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as cell growth inhibition incubated for 68 hrs by MTT assay
    [PMID: 34665635]
    PC-3 IC50
    13.01 3
    Compound: Parthenolide
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    [PMID: 27232656]
    RPMI-8226 GI50
    8.2 3
    Compound: Parthenolide
    Growth inhibition of human RPMI-8226 cells
    Growth inhibition of human RPMI-8226 cells
    [PMID: 38107170]
    RPMI-8226 GI50
    8.2 3
    Compound: 1; PTL
    Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    RXF 393 GI50
    12.2 3
    Compound: 1; PTL
    Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    SF-268 GI50
    25.1 3
    Compound: 1; PTL
    Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    SF-295 GI50
    28.9 3
    Compound: 1; PTL
    Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    SF-539 GI50
    18.9 3
    Compound: 1; PTL
    Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    SK-MEL-2 GI50
    16.2 3
    Compound: 1; PTL
    Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    SK-MEL-28 GI50
    21 3
    Compound: 1; PTL
    Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    SK-MEL-28 IC50
    4.9 3
    Compound: Parthenolide
    Cytotoxicity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 68 hrs by MTT assay
    Cytotoxicity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 68 hrs by MTT assay
    [PMID: 34665635]
    SK-MEL-5 GI50
    17.4 3
    Compound: 1; PTL
    Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    SK-OV-3 GI50
    54.7 3
    Compound: 1; PTL
    Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    SN12C GI50
    22.8 3
    Compound: 1; PTL
    Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    SNB-19 GI50
    70.9 3
    Compound: 1; PTL
    Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    SNB-75 GI50
    48.4 3
    Compound: 1; PTL
    Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    SW-620 GI50
    14.5 3
    Compound: 1; PTL
    Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    TK-10 IC50
    6.4 3
    Compound: PTD
    Growth inhibition of human TK10 cells measured after 24 hrs by SRB assay
    Growth inhibition of human TK10 cells measured after 24 hrs by SRB assay
    [PMID: 27448920]
    U-251 GI50
    41.5 3
    Compound: 1; PTL
    Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    U-87MG ATCC IC50
    4.86 3
    Compound: Parthenolide
    Cytotoxicity against human U87MG cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human U87MG cells assessed as decrease in cell viability after 48 hrs by MTT assay
    [PMID: 27232656]
    UACC-257 GI50
    14.4 3
    Compound: 1; PTL
    Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    UACC-62 GI50
    16.8 3
    Compound: 1; PTL
    Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    UACC-62 IC50
    15 3
    Compound: PTD
    Growth inhibition of human UACC62 cells measured after 24 hrs by SRB assay
    Growth inhibition of human UACC62 cells measured after 24 hrs by SRB assay
    [PMID: 27448920]
    UO-31 GI50
    41.9 3
    Compound: 1; PTL
    Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28525840]
    体外実験

    Parthenolide (PTL) has a dose-dependent growth inhibition effect on NSCLC cells Calu-1, H1792, A549, H1299, H157, and H460. Parthenolide can induce cleavage of apoptotic proteins such as CASP8, CASP9, CASP3 and PARP1 both in concentration- and time-dependent manner in tested lung cancer cells, indicating that apoptosis is trigged after Parthenolide exposure. In addition to induction of apoptosis, Parthenolide also induces G0/G1 cell cycle arrest in a concentration-dependent manner in A549 cells and G2/M cell cycle arrest in H1792 cells[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    体内実験

    Only Parthenolide, the HDAC inhibitor with anti-inflammatory features, displayed a potent anti-apoptotic effect in Phb1 KO hepatocytes. Indeed, TSA and Parthenolide-treated hepatocytes showed increased levels of FXR, and reduced levels of CYP7A1, HDAC4, TNFα, TRAIL and Bax suggesting a less toxic effect of bile acids as a results of specific HDAC inhibition, resulting in the attenuation of the Phb1 KO hepatocytes apoptotic response. Importantly, Parthenolide exerts a protective effect from the liver injury after BDL in Phb1 KO mice. Indeed, Parthenolide treatment results in a reduction of the mortality rate of this mice after BDL associated with a lower apoptotic response as revealed by a reduction of necrotic areas, Tunel-staining, as well as decreased ALT (8431±957 vs.4225±210 U/L) and AST (4805±300 vs.2242±438 U/L) activities compared to control Phb1 KO mice[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    臨床実験
    分子量

    248.32

    分子式

    C15H20O3

    CAS 番号
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    C/C1=C\CC[C@@](C)(O2)[C@H]2[C@@H](OC(C3=C)=O)[C@H]3CC1

    Structure Classification
    Initial Source
    輸送条件

    Room temperature in continental US; may vary elsewhere.

    保管条件
    Powder -20°C 3 years
    In solvent -80°C 6 months
      -20°C 1 month
    溶剤 & 溶解度
    体外: 

    DMSO : ≥ 100 mg/mL (402.71 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : < 0.1 mg/mL (insoluble)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.0271 mL 20.1353 mL 40.2706 mL
    5 mM 0.8054 mL 4.0271 mL 8.0541 mL
    10 mM 0.4027 mL 2.0135 mL 4.0271 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます:C1V1 = C2V2

    濃度 (開始)

    C1

    ×
    体積 (開始)

    V1

    =
    濃度 (終了)

    C2

    ×
    体積 (終了)

    V2

    体内:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (10.07 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    • Protocol 2

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (8.38 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    純度とドキュメンテーション

    純度: 99.91%

    参考文献
    細胞実験
    [2]

    Human lung cancer cell lines are seeded in 96-well plates and treated on the second day with the given concentration of Parthenolide (0, 5, 10, 20 μM) for another 48 hours and then subjected to SRB or MTT assay. For SRB assay, live cell number is estimated as described earlier. After treatment, the medium is discarded firstly. In order to fix the adherent cells, 100 μL of cold trichloroacetic acid (10% (w/v)) are adding to each well and incubating at 4°C for at least 1 hour. The plates are then washed five times with deionized water and dried in the air. Each well are then added with 50 μL of SRB solution (0.4% w/v in 1% acetic acid) and incubated for 5 min at room temperature. The plates are washed five times with 1% acetic acid to remove unbound SRB and then air dried. The residual bound SRB is solubilized with 100 μL of 10 mM Tris base buffer (pH 10.5), and then read using a microtiter plate reader at 495 nm. The MTT assay is executed. 20 μL MTT (5 mg/mL) are added to each sample and incubate at 37°C for 4 h, then 100 μL solubilization solution are added. Cell viability is determined at 595 nm[2].

    MedChemExpress (MCE) はこれらの方法の精度を確認していません。 こちらは参照専用です。

    動物実験
    [3]

    Mice[3]
    Phb1 KO mice are used. Males from 8-12 weeks of age are treated. Parthenolide is intraperitoneally injected at a dose of 3 mg/kg 24 h and 1h before bile duct ligation (BDL) or twice a week during two weeks. Liver specimens are snap-frozen for subsequent analysis[3].

    MedChemExpress (MCE) はこれらの方法の精度を確認していません。 こちらは参照専用です。

    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 4.0271 mL 20.1353 mL 40.2706 mL 100.6765 mL
    5 mM 0.8054 mL 4.0271 mL 8.0541 mL 20.1353 mL
    10 mM 0.4027 mL 2.0135 mL 4.0271 mL 10.0677 mL
    15 mM 0.2685 mL 1.3424 mL 2.6847 mL 6.7118 mL
    20 mM 0.2014 mL 1.0068 mL 2.0135 mL 5.0338 mL
    25 mM 0.1611 mL 0.8054 mL 1.6108 mL 4.0271 mL
    30 mM 0.1342 mL 0.6712 mL 1.3424 mL 3.3559 mL
    40 mM 0.1007 mL 0.5034 mL 1.0068 mL 2.5169 mL
    50 mM 0.0805 mL 0.4027 mL 0.8054 mL 2.0135 mL
    60 mM 0.0671 mL 0.3356 mL 0.6712 mL 1.6779 mL
    80 mM 0.0503 mL 0.2517 mL 0.5034 mL 1.2585 mL
    100 mM 0.0403 mL 0.2014 mL 0.4027 mL 1.0068 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます:C1V1 = C2V2

    濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

     

    カスタマ需要量 *

    お名前 *

     

    タイトル

    メールアドレス *

     

    電話番号 *

    デパートメント

     

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

         

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Parthenolide
    製品番号:
    HY-N0141
    数量:
    MCE 日本正規代理店: